Followers | 401 |
Posts | 17542 |
Boards Moderated | 0 |
Alias Born | 07/14/2003 |
Thursday, March 28, 2024 9:03:22 AM
Date: Thursday, March 28, 2024
Time: 10:00 AM PT/1:00 PM ET
Discover an investment opportunity with Ethema by joining our highly anticipated webinar. Led by CEO Shawn Leon and our experienced team, we believe Ethema is poised to transform the behavioral healthcare space.
During this exclusive event, we will share our roll-up strategy and long-term growth plans, as well as go deeper into the company’s mission and values.
Untitled design (6)
Sign up below to attend this FREE webinar on March 28, 2024 at 10:00 AM PT/1:00 PM ET. Do it now as these spots will fill up fast!
Thank you for signing up for our webinar!
You’ll receive an email to confirm your attendance.
Untitled design (6)
Ethema is operating a recession-proof business existing outside of economic uncertainty2. Even in times of economic recession, depression, mental illness and substance use disorders persist and can even exacerbate. Ethema is moving beyond the market noise to capture big returns in this underserved and underdeveloped sector.
image 5
Growth Strategy
Our long-term capital appreciation growth strategy focuses on increased revenue per square foot at each facility in our portfolio (efficiency ratio).
image 3
Rollup Strategy
Rising net collections month over month driven by our rollup strategy and technology advancements in billing and collections.
image 4
Core Asset Values
Careful selection of choice property acquisitions with upside core asset values.
Sources:
https://www.biospace.com/article/u-s-behavioral-health-market-size-report-2021-to-2030/
https://www.sciencedaily.com/releases/2019/09/190903120522.htm#:~:text=%22Individuals%20who%20experienced%20even%20a,the%20recession%2C%22%20Forbes%20explains
Disclaimer:
Recent GRST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:54:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:55:26 PM
- Form 1-A POS - • Edgar (US Regulatory) • 10/20/2023 07:29:40 PM
- Form 1-A POS - • Edgar (US Regulatory) • 08/29/2023 07:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:37:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 12:43:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 04:51:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 06:56:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM